China's SFDA Sets New GMP Standards
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI -- China's State Food and Drug Administration issued revised good manufacturing practice regulations Oct. 24 in an effort to increase quality systems standards for pharmaceutical manufacturers. The new standards are scheduled to go into effect Jan. 1, replacing the current GMP standards, which were implemented in 1998
You may also be interested in...
China Eager To Establish Pharmacovigilance System – SFDA Officials
SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai
China Eager To Establish Pharmacovigilance System – SFDA Officials
SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai
China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules
SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January